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Poster Session-I 91duration of hospital stay (Table). In summary, within the first 100
days after HCT, transplantation with MA MRD, NMA MRD and
NMA UCB has similar costs while MA UCB HCT is more costly.
These higher costs can be attributed to lengthier hospital stay due
to slower engraftment and a higher incidence of graft failure. Strat-
egies to enhance engraftment (e.g. better HLA matched units, in-
creasing cell dose using two units) will decrease the costs of UCB
transplantation. Long-term costs of UCB HCT may be lower due
to the lower incidence of chronic GVHD, but this warrants further
investigation.
Multivariate analysis for costs within the first 100 days follow-
ing HCT
Variable Ratio (95% CI) P-valueTransplant type
MA MRD 1.0
MA UCB 1.3 (1.1-1.5) 0.05
NMA MRD 1.0 (0.9-1.2) 0.82
NMA UCB 1.0 (0.8-1.2) 0.96Graft failure
No 1.0
Yes 1.8 (1.7-1.9) \0.001Dialysis
No 1.0
Yes 1.3 (1.1-1.5) 0.05Mechanical ventilation
No 1.0
Yes 1.3 (1.2-1.4) 0.004Hospital stay, tertiles
\32 days 1.0
32-48 days 1.0 (0.8-1.2) 0.98
.48 days 2.1 (1.9-2.3) \0.001Other variables considered in themodel included age at HCT, Karnofsky
performance score at HCT, disease risk, previous transplant, CMV sta-
tus, acute GVHD, hepatic veno-occlusive disease, and total (inpatient
and outpatient) medical encounters (HLA match correlated with trans-
plant type and was not included)250
PREEMPTIVE RITUXIMAB TREATMENT MAY REDUCE THE INCIDENCE OF
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) IN PA-
TIENTS WITH EBV REACTIVATION AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Kindwall-Keller, T.L.1, Cooper, B.W.1, Laughlin, M.J.1, Gerson, S.L.1,
Barr, P.1, Erinc, S.2, Creger, R.J.1, Lazarus, H.M.1 1UniversityHospitals
of Cleveland, Case Medical Center, Cleveland, OH; 2University Hospitals
of Cleveland, Case Medical Center, Cleveland, OH
PTLD resulting from EBV reactivation after stem cell transplan-
tation is a potentially fatal complication observed with T-cell de-
pleted, matched unrelated donor (MUD), and umbilical cord
blood (UCB) transplants, and the use of ATG-associated condition-
ing. Real-time quantitative (quant) PCR for EBV DNA is a highly
sensitive and specific test for EBV reactivation. Since 5/2006, we
screen allogeneic transplant recipients using quant PCR for EBV
DNA weekly until day 100 and monthly thereafter. If EBV DNA ti-
ter is.1000 copies, we initiate rituximab 375mg/m2 IVweekly for 4
weeks. Of 53 allogeneic transplants performed between 5/2006 and
8/2008, 14 patients (pts) (26%) (11 male, 3 female) had EBV reacti-
vation. Median age was 50.5 (range 20–71) yrs. All pts with EBV re-
activation had high-risk malignancies (secondary AML, AML,
CML, CLL, aplastic anemia, Hodgkin’s lymphoma, myelofibrosis).
Graft sources were UCB (N5 8), matched-related donor (MRD) (N
5 4), and MUD (N 5 2). Myeloablative conditioning was used in 3
pts; 11 patients (UCB, N 5 7) received reduced-intensity (RIC) or
nonmyeloablative (NST) regimens. ATGwas included in the condi-
tioning regimen in all pts except for 2 MUD pts and 2 MRD pts. All
pts received cyclosporine or FK 506 based GVHD prophylaxis. Me-
dian follow up is 289 (range 76–489) days. Relapse occurred in 3 pts
with an overall survival of 79%. One pt died of treatment-related
mortality; 2 pts died of disease relapse. Grade 2–4 acute GVHDwas seen in 7; 2/11 pts had extensive chronic GVHD. Median time
to diagnosis of EBVpositivitywasT160.5 (range 21–302)with ame-
dian EBV titer of 1720 (range 656–5700). Twelve pts received ritux-
imab. One pt had treatment initiated with an EBV titer\1000. This
pt had a positive qualitative EBVPCR test one week prior to the pos-
itive quant EBV PCR (656). All but one pt became EBV negative by
the end of the course of rituximab. This pt went on to receive 6
weekly treatments of rituximab and was started on valganciclovir.
One pt did not receive rituximab for an EBV titer of 886; 6 weeks
later had an EBV titer .1,000,000 and died of multi-organ failure.
Majority of pts received RIC orNST regimens or anUCB transplant
regimen using ATG. Given the morbidity and mortality of PTLD,
weekly testing for EBV DNA by quant PCR with preemptive treat-
ment with rituximab for pts with EBV titers.1000 may be effective
in preventing EBV associated PTLD.251
CHG WATERLESS BATH SYSTEM SIGNIFICANTLY REDUCED BSI IN PEDI-
ATRIC BMT PATIENTS
Rosselet, R.M., Termuhlen, A.M., Skeens, M., Garee, A., Laudick, M.,
Ryan-Wenger, N. Nationwide Children’s Hospital, Columbus, OH
Objectives: The primary objective is to determine whether pedi-
atric blood and marrow transplant (BMT) patients bathed daily with
chlorhexidine gluconate (CHG) waterless bath system have lower in-
cidence of Staphylococcus epidermis blood stream infections and total
blood stream infections (BSI) compared to patients bathed with
the standard CHG soap and water method. Secondary objectives
are to determine the time efficiency and cost effectiveness of water-
less bath system versus the standard soap and tap water bath.
Background: With continuous improvements in BMT technol-
ogy and increasing survival, infection remains a leading cause ofmor-
bidity and mortality among transplant patients.
Methods: A non-equivalent two-group quasi-experimental study
was conducted using historical controls (N5 25) who received soap
and water bathing during their admission for BMT versus patients
bathed with CHG waterless bath system (N 5 25). A time and mo-
tion analysis (N 5 20) during the bathing procedure was conducted
by an independent observer, who recorded number of minutes spent
on the entire bathing procedure and the amount and type of mate-
rials/supplies used for each type bath. Data regarding infections
were collected by chart review. Outcomes measured included inci-
dence of total BSI and Staphylococcus epidermis BSI. Secondary out-
comes included the time and cost of the two bathing systems.
Results: Independent t-tests were used to compare groups. Pedi-
atric BMT patients bathed with CHG waterless bath intervention
had significantly fewer BSI overall (x vs. y) and Staphylococcus epidermis
BSI (x vs. y) (p5 0.017, 0.009 respectively). The cost of materials per
bath was nearly identical, ($14.40 per soap and tap water bath versus
$14.23 per CHGwaterless bath). However, staff direct care time was
nearly three times longer for tap water bath (18.3 minutes per bath)
than the waterless bath (6.6 minutes per bath). The time difference
was statistically significant (t 5 4.537, p\ 0.001), which translates
to lower cost for the waterless bath method.
Conclusions:Daily bathing of patients with CHG waterless bath
system significantly decreased BSI, especially with Staphylococcus
epidermis. It is an easy, time-efficient, cost-effective intervention to
decrease these infections in pediatric patients undergoing a BMT.252
COMPARISION AND COST EFFECTIVENESS OF BRONCHOSCOPIC AND
NON-BRONCHOSCOPIC BRONCHOALVEOLAR LAVAGE IN HEMATOLOGI-
CAL MALIGNANCIES AND STEM CELL RECIPIENTS
Ghosh, S., Finch, C.G., Champlin, R.E., Pravinkumar, S.E. University of
Texas M.D. Anderson Cancer Center, Houston, TX
Introduction: Pulmonary infiltrates are common in critically ill
patients with hematological malignancies and also in post stem cell
transplant (SCT) recipients. Radiological changes of parenchymal
infiltrates are non-specific and can be caused by infection, inflamma-
tion, fluid, and parenchymal bleeding. Bronchoalveolar lavage (BAL)
is commonly performed for microbiological sampling.
92 Poster Session-IBronchoscopic BAL (B-BAL) is performed by physicians, using
video-bronchoscope. Non-bronchoscopic BAL (NB-BAL) is per-
formed by respiratory therapists (RT), without direct visualization
of the lower airways. Generally, B-BAL is considered more effective
thanNB-BALdue to concern thatNB-BALperformed byRT can be
associated with higher incidence of complications, especially bleed-
ing. We compared the two methods for obtaining BAL and studied
themicrobiological yield, safety and cost-effectiveness of B-BAL and
NB-BAL in critically ill cancer patients.
Method: Following IRB approval, medical records of all intu-
bated and mechanically ventilated adult ICU patients with pulmo-
nary infiltrates, who underwent either B-BAL or NB-BAL between
8/1/2006 and 10/31/2006, were retrospectively studied. B-BAL
was performed by intensivist or pulmonologist and NB-BAL was
performed using 16Fr Kimberly Clark’s protected BAL catheter,
by experienced and skilled RT according to specific department pol-
icy. The BAL samples were taken from the lower lobe bronchial seg-
ments.Table 1. A comparison of B-BAL and NB-BAL in patients with
hematological malignancies.
Patient Charecteristics n B-BAL NB-BAL44 22 22
Age yrs
Median 52 49 55
Range 20-79 20-79 28-72
M/F 29/15 15/7 14/8Diagnosis
Leukemia 16 10 6
Lymphoma 13 5 8
SCT recipients 13 7 6
Myeloma 1 0 1
Hypereosinophilic syndrome 1 0 1WBC count K/UL
Median 3.3 0.3 5.0
Range 0.1-102 0.1-18 0.1-102Platelet count K/UL
Median 42 29 59
Range 5-321 5-247 23-321
Complications 0 0 0
Microbiological yield 20/44 (46%) 11/22 (50%) 9/22 (41%)Cost per procedure $ 2427 125
SCT recipients
Platelet count K/UL
Median 51 27 52
Range 19-247 19-247 24-98WBC count K/UL
Median 5.2 6.6 3.25Range 0.1-21.2 3.3-9.0 0.1-21.2
Microbiological yield 7/13 (54%) 4/7 (57%) 3/6 (50%)Results:During the study period, 44 critically ill patients with he-
matological malignancies including 13 SCT recipients underwent
BAL. Four patients had received SCT within the prior 4 weeks of
BAL. An equal number of NB-BAL and B-BAL was performed. Pa-
tient characteristics,WBC counts, platelet counts, procedure related
complications, microbiological yield and cost per procedure associ-
ated with B-BAL and NB-BAL are shown in table 1. The most fre-
quently identified organisms were Pseudomonas aeruginosa,
Coagulase negative staphylococcus, Stenotrophomonas maltophilia,
and Candida spp.
Conclusion: Both B-BAL and NB-BAL can be safely performed
in patients with hematological malignancies including SCT recipi-
ents. Microbiological yield is similar between physician performed
B-BAL and RTperformedNB-BAL in critically ill patients with pul-
monary infiltrates. However, the cost of B-BAL is 20 times higher
thanNB-BAL for similar yield, due to physician resource utilization.
Hence, NB-BAL should be considered as a safe alternative whenever
feasible.253
CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF DISSEMI-
NATED TRICHOSPORONOSIS: SURVEY OF 67 PATIENTS WITH HEMATO-
LOGICAL DISEASE
Fukuda, T.1, Sugita, T.2, Takakura, S.3, Takata, T.4, Kushima, H.5,
Takaue, Y.1, Tamura, K.4, Tokimatsu, I.5 1National Cancer Center Hos-
pital, Tokyo, Japan; 2Meiji Pharmaceutical University; 3Kyoto University
Hospital; 4Fukuoka University; 5Oita University
Background: Disseminated infection by Trichosporon species
(DT) is an uncommon but frequently fatal mycosis in neutropenic
patients, including recipients of hematopoietic stem cell transplanta-
tion (HSCT). However, little is known about the clinical character-
istics and treatment outcome of DT due to its rarity.
Methods: A questionnaire was sent to 468 hospitals in Japan to
survey DT, which was defined as infectious symptoms associated
with positive blood culture for Trichosporon species. In selected pa-
tients, genetic subtypes and antifungal susceptibility of the isolates
were analyzed.
Results: Between 2000 and 2007, 67 patients (median age, 57
years: range, 16–78) with a variety of hematological diseases devel-
oped DT. The diagnosis included acute myeloid leukemia (n 5
39), acute lymphoblastic leukemia (8), chronic myeloid leukemia
(6), and lymphoma (6), and 28 patients (42%) were recipients of
HSCT. At the onset of DT, 55 patients (82%) had an absolute neu-
trophil count below 500 /mm3, and 58 patients (87%) had been re-
ceiving antifungal agents, including micafungin (MCFG) in 39
patients. In 35 patients (52%), Trichosporon species were detected
in various organs including lung (n 5 18), kidney (12), heart (6),
and skin (6). A beta-D-glucan test was positive in 43 of the 62 eval-
uated patients (median, 96 pg/ml; range, 22–3961). Whereas 2 iso-
lates of T. asahi appeared to be resistant to all antifungal agents
including azoles, 22 isolates showed good susceptibility to voricona-
zole, but not to MCFG. Although 56 of the 67 patients (84%) re-
ceived various antifungal agents for DT, the mortality rate within
30 days was 67% (median survival time, 13 days). Overall survival
was significantly better in patients who received azoles rather than
amphotericin products without azole (p5 0.0002). In a multivariate
analysis, treatment without azoles for DT and recipients of HSCT
were associated with a higher probability of day-30 mortality after
the development of DT.
Conclusions:Our study suggests that most cases of DT occurred
as a breakthrough infection, especially in patients who had received
MCFG. Although mortality after the development of DT was high,
it is possible that prompt initiation of treatment with azoles may
improve survival.254
IMPACT OF PRE-STEM CELL TRANSPLANT FERRITIN LEVELS ON LATE
TRANSPLANT COMPLICATIONS. A LANDMARK ANALYSIS TO DETERMINE
POTENTIAL ROLE OF IRON CHELATION IN IMPROVING TRANSPLANT
OUTCOMES
Efebera, Y.1, Saliba, R.M.1, Thandi, R.S.1, Popat, U.1, De Lima, M.1,
Alousi, A.1, Hosing, C.1, Ledford, M.2, Champlin, R.1, Giralt, S.1 1Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX; 2Novartis
Pharmaceuticals, East Hanover, NJ
Background: Iron overload has been associated with increased
treatment-related mortality (TRM) in patients with AML/MDS un-
dergoing hematopoietic stem cell transplantation (HSCT). Defara-
sinox (D) is an orally-active iron chelator that at doses of 20 and
30 mg/kg maintain or reduce liver iron concentration in transfusion
dependent patients with MDS or hemoglobinopathies. The most
common adverse events associated with D are skin rash (26%), ab-
dominal pain (21%), and creatinine elevation (20%). These adverse
effect overlap with commonly acute side effects seen after allograft-
ing and together with the creatinine elevations make exploring the
role of D early after HSCT (ie first 90 days) difficult. Notwithstand-
ing, a significant proportion of non-relapse deaths still occur be-
tween 3 and 12 months post HSCT. Since high ferritin (F) levels
pre HSCT have been associated with increases in NRM rates post
HSCT we hypothesized that this relationship would persist even
in patients surviving more than 3 months post SCT, which would
suggest a potential role for iron chelation in patients surviving at least
3 months post HSCT.
